The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Open accessAbstract
BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events. CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov number, NCT00006343 [ClinicalTrials.gov].)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationA minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Self-citationDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationFused transcript of abl and bcr genes in chronic myelogenous leukaemia
Shtivelman, E., Lifshitz, B., Gale, R. P., & Canaani, E. (1985) · Nature · doi:10.1038/315550a0 · Cited by 1,611
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Self-citationHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Self-citationPrognostic discrimination in "good-risk" chronic granulocytic leukemia
Sokal, J., Cox, E., Baccarani, M., Tura, S., Gomez, G., Robertson, J., Tso, C., Braun, T., Clarkson, B., & Cervantes, F. (1984) · Blood · doi:10.1182/blood.v63.4.789.789 · Cited by 1,214
Self-citationGraham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
Talpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,019
Konopka, J. B., Watanabe, S. M., & Witte, O. N. (1984) · Cell · doi:10.1016/0092-8674(84)90438-0 · Cited by 892
Structural organization of the bcr gene and its role in the Ph′ translocation
Heisterkamp, N., Stam, K., Groffen, J., de Klein, A., & Grosveld, G. (1985) · Nature · doi:10.1038/315758a0 · Cited by 882
Active transport of imatinib into and out of cells: implications for drug resistance
Thomas, J., Wang, L., Clark, R. E., & Pirmohamed, M. (2004) · Blood · doi:10.1182/blood-2003-12-4276 · Cited by 643
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635
Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia
Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.-L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370402 · Cited by 543
Self-citationRousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J. M., Maarek, O., Blanchet, O., Marit, G., Gluckman, E., Reiffers, J., et al. (2007) · Blood · doi:10.1182/blood-2006-03-011239 · Cited by 538
Self-citationSilver, R. T., Woolf, S. H., Hehlmann, R., Appelbaum, F. R., Anderson, J., Bennett, C., Goldman, J. M., Guilhot, F., Kantarjian, H. M., Lichtin, A. E., et al. (1999) · PubMed · Cited by 463
Self-citationChronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders
Bonifazi, F., de Vivo, A., Rosti, G., Guilhot, F., Guilhot, J., Trabacchi, E., Hehlmann, R., Hochhaus, A., Shepherd, P. C. A., Steegmann, J. L., et al. (2001) · Blood · doi:10.1182/blood.v98.10.3074 · Cited by 321
Self-citationWillis, S. G., Lange, T., Demehri, S., Otto, S., Crossman, L., Niederwieser, D., Stoffregen, E. P., McWeeney, S., Kovacs, I., Park, B., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1036 · Cited by 302
Self-citationDiscontinuation of imatinib therapy after achieving a molecular response
Cortes, J., O'Brien, S., & Kantarjian, H. (2004) · Blood · doi:10.1182/blood-2004-04-1335 · Cited by 280
Self-citationMechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias
Shah, N. P., & Sawyers, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206942 · Cited by 216
Roy, L., Guilhot, J., Krahnke, T., Guerci-Bresler, A., Druker, B. J., Larson, R. A., O'Brien, S., So, C., Massimini, G., & Guilhot, F. (2006) · Blood · doi:10.1182/blood-2006-02-001495 · Cited by 216
Self-citationChu, S., Xu, H., Shah, N. P., Snyder, D. S., Forman, S. J., Sawyers, C. L., & Bhatia, R. (2005) · Blood · doi:10.1182/blood-2004-03-1114 · Cited by 209
Griswold, I. J., MacPartlin, M., Bumm, T., Goss, V. L., O'Hare, T., Lee, K. A., Corbin, A. S., Stoffregen, E. P., Smith, C., Johnson, K., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02202-05 · Cited by 200
Self-citationBaccarani, M., Rosti, G., de Vivo, A., Bonifazi, F., Russo, D., Martinelli, G., Testoni, N., Amabile, M., Fiacchini, M., Montefusco, E., et al. (2002) · Blood · doi:10.1182/blood.v99.5.1527 · Cited by 166
Self-citationMauro, M. J., Druker, B. J., & Maziarz, R. T. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.10.017 · Cited by 135
Self-citationOutcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.
Merante, S., Orlandi, E. M., BERNASCONI, P. P., Calatroni, S., Boni, M., & Lazzarino, M. (2005) · PubMed · Cited by 107
Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment
Roche‐Lestienne, C., & Preudhomme, C. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70025-0 · Cited by 70
LICHTMAN, M., Spivak, J. L., Boxer, L. A., Shattil, S. J., & HENDERSON, E. (2000) · Elsevier eBooks · doi:10.1016/b978-012448510-5/50138-2 · Cited by 41
Breccia, M., Diverio, D., Pane, F., Nanni, M., Russo, E., Biondo, F., Frustaci, A. M., Gentilini, F., & Alimena, G. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.03.011 · Cited by 32
Cited by
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Metadata
- Authors
- Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., Cervantes, F., Hochhaus, A., Powell, B. L., Gabrilove, J. L., Rousselot, P., Reiffers, J., Cornelissen, J. J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J. L., Radich, J. P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L., & Larson, R. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-12-07
- Volume
- 355
- Issue
- 23
- Pages
- 2408-2417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2107268345
- Cited by
- 3,488
- References
- 35
- FWCI
- 132.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.